CD8A and neoplasm: We generated immortalised lymphoblastoid cell lines (LCLs) by infecting human PBMCs with Epstein‒Barr virus (EBV) for 21 days to further explore whether targeting RIG-I could also enhance the anti-tumour function of human CD8+ T cells.